Chemotherapy of hormonally unresponsive prostatic carcinoma
DeKernion, J.B.; Lindner, A.
Urologic Clinics of North America 11(2): 319-326
1984
ISSN/ISBN: 0094-0143 PMID: 6233779 Document Number: 237207
The national Prostatic Cancer Project has evaluated single and combination chemotherapeutic agents for the treatment of patients with advanced prostatic cancer that has been unresponsive to hormonal therapy. Although regression rates have been modest, a number of drugs have shown some efficacy and are now undergoing testing in combination. Current trials of the LH-RH agonists and the antiandrogen flutamide are in progress. These trials have demonstrated a role for chemotherapy in the treatment of the patient who has failed hormonal therapy.
Document emailed within 1 workday
Related Documents
Holmes, F.A.; Yap, H.Y.; Esparza, L.; Buzdar, A.U.; Hortobagyi, G.N.; Blumenschein, G.R. 1984: Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer Seminars in Oncology 11(3 Suppl 1: 28-31Beckley, S.; Wajsman, Z.; Slack, N.; Mittelman, A.; Murphy, G.P. 1980: The chemotherapy of prostatic carcinoma Scandinavian Journal of Urology and Nephrology. Supplementum 55: 151-162
Ebert, T.; Bendhack, M.L. 1997: Prostatic carcinoma--diagnosis, hormone therapy, radio- and chemotherapy Der Urologe. Ausg. a 36(6): 570-577
Bogdanowicz, J.F.; Bentvelsen, F.M.; Oosterom, R.; Schroeder, F.H. 1991: Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia Scandinavian Journal of Urology and Nephrology. Supplementum 138: 97-103
Kumamoto, Y.; Tsukamoto, T.; Umehara, T.; Harada, M.; Shimazaki, J.; Fuse, H.; Oshima, H.; Takeuchi, H.; Yoshida, O.; Okada, K. 1990: Clinical studies on endocrine therapy of prostatic carcinoma (3): Histopathological features of prostatic carcinoma and its prognosis Hinyokika Kiyo. Acta Urologica Japonica 36(3): 295-305
T'Jean, M. 1984: Review of results obtained from tumors unresponsive to chemotherapy Revue Medicale de Liege 39(3): 103-107
Szklarz, E.; Zawirska, B.; Gruszka, S.; Plamieniak, Z.; Wrezlewicz, W.; Moszczyński, L.; Dzik, T. 1978: Hormonally active adrenocortical carcinoma and its porphyrin content Endokrynologia Polska 29(1): 53-61
Weinberg, D.S.; Weidner, N. 1993: Concordance of DNA content between prostatic intraepithelial neoplasia and concomitant invasive carcinoma. Evidence that prostatic intraepithelial neoplasia is a precursor of invasive prostatic carcinoma Archives of Pathology and Laboratory Medicine 117(11): 1132-1137
Shimazaki, J.; Fuse, H.; Akimoto, S.; Sumiya, H.; Akakura, K.; Ichikawa, T. 1988: Prostatic carcinoma. I: Androgen dependency of prostatic carcinoma Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(4 Pt: 2-1): 909-916
Sendur, M.A.N.; Dagdelen, S.; Abbasoglu, O.; Erbas, B.; Sokmensuer, C.; Ziyal, I.; Erbas, T. 2014: Recurrent parathyroid carcinoma with spinal metastases unresponsive to cinacalcet therapy Journal of Buon: Official Journal of the Balkan Union of Oncology 19(3): 863-864
Sáenz de Chirife, A.M.; Bassi, A.M.; Celeste, F.; Bergdolt, D. 1991: Specific prostatic antigen in prostatic carcinoma: its relationship with tumor differentiation and clinical course Archivos Espanoles de Urologia 44(4): 405-409
Strohmenger, P. 1980: Prostatic adenoma--prostatic carcinoma. Questions from general practice. II. Therapy Zfa. Zeitschrift für Allgemeinmedizin 56(28): 1793-1797
Pretlow, T.G.; Whitehurst, G.B.; Pretlow, T.P.; Hunt, R.S.; Jacobs, J.M.; McKenzie, D.R.; McDaniel, H.G.; Hall, L.M.; Bradley, E.L. 1982: Decrease in creatine kinase in human prostatic carcinoma compared to benign prostatic hyperplasia Cancer Research 42(11): 4842-4848
Bologna, M.; Festuccia, C.; Vicentini, C.; Muzi, P.; Biordi, L.; De Nicola, G.; Ventura, T. 1991: Establishment and characterization of a human prostatic carcinoma cell strain obtained from exfoliated tumor cells after prostatic massage Tumori 77(1): 70-75
Abdalla, A.M.; Oliver, J.A. 1971: SV40 virus transformed prostatic carcinoma in the hamster. I. Comparisons of lactate dehydrogenase isoenzymes with human prostatic cancer Investigative Urology 8(4): 442-447
Maygarden, S.J.; Strom, S.; Ware, J.L. 1992: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia Archives of Pathology and Laboratory Medicine 116(3): 269-273
Shiran, M.S.; Tan, G.C.; Sabariah, A.R.; Rampal, L.; Phang, K.S. 2007: P63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions Medical Journal of Malaysia 62(1): 36-39
Schubert, J.; Gorski, J. 1983: Zum biologischen Verhalten des Prostatakarzinoms. II: Klinisch-operative Studien zur lymphogenen Metastasierung des Prostatakarzinoms - Le comportement biologique du cancer prostatique. II: Etudes clinicochirurgicales sur les métastases lymphogènes du cancer prostatique - Biological behaviour of prostatic carcinoma. II. Clinical operative studies of lymphatic metastasizing of prostatic carcinoma der Urologe. Ausgabe a 22: 356-359
Tsukamoto, T.; Fukui, I.; Kihara, K.; Goto, S.; Kitahara, S.; Kobayashi, T.; Kojima, S.; Oshima, H. 1996: Combined hormone-chemotherapy for stage D2 prostatic cancer: starting time of chemotherapy in relation to hormone therapy Hinyokika Kiyo. Acta Urologica Japonica 42(5): 351-356
Leńko, J.; Marczyńska, A.; Kulpa, J.; Kwinta, A.; Bugajski, A. 1986: Biochemical control investigations (determinations of prostatic phosphatase--carcinoembryonic antigen alkaline phosphatase) in patients treated for prostatic carcinoma. Preliminary estimation of effectiveness Materia Medica Polona. Polish Journal of Medicine and Pharmacy 18(4): 238-243